Caffeinol Study: A Trial of Caffeine plus Ethanol in Acute Stroke [SPOTRIAS]

Completed

Phase N/A Results

Summary of Purpose

To determine the lowest doses required to produce blood levels of caffeine and ethanol (caffeinol) in the target range (8-10 ug/mL and 30-50 mg/dL) and to determine the safety and tolerability of intravenous caffeinol in patients with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 28 July 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • NINDS grant T32NS07412 and NINDS grant 1R01NS040974-01A1

Trial Design

FDA-approved, open-label, single-arm, dose-escalation pilot study.

Contacts

Not available